Current Patterns and Best Practices for Prescribing Novel Heart Failure Medications in Children: A Science Advisory From the American Heart Association
Robust evidence from randomized controlled trials of novel heart failure medications in adults has demonstrated improved quality of life, reduced hospitalizations, and decreased mortality, informing current treatment guidelines. In contrast, data supporting the clinical benefits of newer heart failure therapies in children remain limited. To assess contemporary prescribing practices and clinician perspectives, we surveyed pediatric heart failure physicians across the United States and Canada regarding the use of angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and iron replacement therapy in children. We also reviewed the existing pediatric literature and summarized reported side effects, dosing experience, and practical guidance for the use of these therapies in the absence of rigorous evidence.
Authors
- Joseph W. Rossano (ORCID: https://orcid.org/0000-0002-8284-0673)
- Aamir Jeewa (ORCID: https://orcid.org/0000-0003-2878-6554)
- Amanda E. Jacobson‐Kelly (ORCID: https://orcid.org/0000-0002-9118-4487)
- David E. Procaccini (ORCID: https://orcid.org/0000-0002-8233-7218)
- Borah J. Hong (ORCID: https://orcid.org/0000-0002-5294-6821)
- Jack F. Price (ORCID: https://orcid.org/0000-0003-2504-7254)
- Vernat Exil
- Jonathan Menachem
- Hugo Martinez
- Kimberly Lin
Publication Details
- Journal
- Circulation Heart Failure
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1161/hhf.0000000000000092
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00